Pancreatic cancer treatment has made significant strides with a new drug, Rasonque, from Revolution Medicines. Clinical trials analyzed by Dr. Monique Yohanan show promising outcomes for stage 4 patients. These patients achieved a median survival time of 13.2 months, a substantial increase compared to 6.7 months with standard chemotherapy. This advancement brings hope against a disease with historically low survival rates.
Recent trial results were shared at the EORTC-NCI-AACR Symposium in Barcelona. The phase 1/2 trial tested daraxonrasib, an oral medication, along with the chemotherapy drugs gemcitabine and nab-paclitaxel. The trial included 61 patients with advanced pancreatic cancer, all untreated for their metastasized conditions.
Pancreatic cancer is challenging to treat, often diagnosed at advanced stages. Chemotherapy alone reduces tumors in 23% to 42% of patients, but cancer usually returns within five to six months, with survival rates between eight and 11 months. Combining daraxonrasib with chemotherapy significantly halted cancer progression in 90.2% of untreated patients.
National Cancer Institute data indicates that only 3% of patients with advanced pancreatic cancer survive for five years post-diagnosis. In the study, with an 18-month median follow-up, 60.7% of tumors shrank, and 8.2% disappeared completely. Overall, cancer stopped progressing in 90.2% of cases.
Patients lived for a median of 12.8 months before cancer progression, nearly doubling the duration typically observed with chemotherapy. The one-year survival rate reached 76.6%.
We are observing notable tumor shrinkages, including complete responses, with durable disease control and median progression-free survival exceeding one year.
Most side effects like rash, diarrhea, fatigue, and low blood cell counts were manageable. Only 5% of patients discontinued treatment due to daraxonrasib.
More than 90% of pancreatic cancers are associated with RAS gene mutations, leading to uncontrolled tumor growth. Daraxonrasib targets this growth signal, representing a significant scientific achievement. Dr. Elena Garralda, symposium chair, sees potential in combining RAS-targeted drugs with existing treatments for lasting benefits.
Despite promising results, the trial’s early-phase, single-group design limits definitive conclusions. The larger, randomized phase 3 trial RASolute-303 aims to compare daraxonrasib and chemotherapy with standard chemotherapy alone, offering clearer insights.
Revolution Medicines, daraxonrasib’s developer, sponsored the trial. Upcoming trials will evaluate the drug’s efficacy on other cancers driven by RAS mutations.

Highlights from Recent News Stories
DEA Dismantles First U.S. Large-Scale Nitazene Lab
Trump Open to Bipartisan Health Care Plan with Democrats
Ty Pennington’s View on Home Renovation and Health
Building Resilience Amid Stress and Uncertainty
How to Prepare for Aging Parents: Practical Steps for Families